MX348083B - Polimorfos macrociclicos, composiciones que comprenden tales polimorfos, y metodos para su uso y fabricacion. - Google Patents

Polimorfos macrociclicos, composiciones que comprenden tales polimorfos, y metodos para su uso y fabricacion.

Info

Publication number
MX348083B
MX348083B MX2013009811A MX2013009811A MX348083B MX 348083 B MX348083 B MX 348083B MX 2013009811 A MX2013009811 A MX 2013009811A MX 2013009811 A MX2013009811 A MX 2013009811A MX 348083 B MX348083 B MX 348083B
Authority
MX
Mexico
Prior art keywords
compounds
compositions
polymorphs
forms
manufacture
Prior art date
Application number
MX2013009811A
Other languages
English (en)
Inventor
Chiu Yu-Hung
Mary Che Tessie
Romero Alex
Ichikawa Yoshi
Shue Youe-Kong
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38661942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX348083(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX348083B publication Critical patent/MX348083B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a formas novedosas de compuestos que presentan una actividad antibiótica de amplio espectro, especialmente formas polimórficas cristalinas y formas amorfas de tales compuestos, composiciones que comprenden tales formas polimórficas cristalinas y formas amorfas de tales compuestos, procesos para su fabricación y uso. Los compuestos y composiciones de la presente invención son útiles en la industria farmacéutica, por ejemplo, en el tratamiento o en la prevención de enfermedades y trastornos relacionados con el uso de antibióticos, quimioterapias, o terapias antivirales, incluyendo pero, sin limitarse a estos ejemplos, colitis, por ejemplo, colitis pseudomembranosa, diarrea asociada con antibióticos; e infecciones causadas por Clostridium difficile ("C. difficile"), Clostrídium perfringens ("C. perfringens"), especies de Staphylococcus, por ejemplo, Staphylococcus resistente a la meticilina, o bien Enterococcus, incluyendo enterococci resistentes a la Vancomicina.
MX2013009811A 2007-01-22 2008-01-22 Polimorfos macrociclicos, composiciones que comprenden tales polimorfos, y metodos para su uso y fabricacion. MX348083B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88195007P 2007-01-22 2007-01-22
US11/831,886 US7378508B2 (en) 2007-01-22 2007-07-31 Polymorphic crystalline forms of tiacumicin B
PCT/US2008/000735 WO2008091554A1 (en) 2007-01-22 2008-01-22 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof

Publications (1)

Publication Number Publication Date
MX348083B true MX348083B (es) 2017-05-25

Family

ID=38661942

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013009811A MX348083B (es) 2007-01-22 2008-01-22 Polimorfos macrociclicos, composiciones que comprenden tales polimorfos, y metodos para su uso y fabricacion.
MX2009007730A MX2009007730A (es) 2007-01-22 2008-01-22 Polimorfos macrocilicos, composiciones que comprenden tales polimorfos, y metodos para su uso y fabricacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009007730A MX2009007730A (es) 2007-01-22 2008-01-22 Polimorfos macrocilicos, composiciones que comprenden tales polimorfos, y metodos para su uso y fabricacion.

Country Status (23)

Country Link
US (5) US7378508B2 (es)
EP (3) EP2468761A1 (es)
JP (2) JP5468388B2 (es)
KR (2) KR20090117924A (es)
CN (2) CN102746353A (es)
BR (1) BRPI0806878A2 (es)
CA (2) CA2880860A1 (es)
CY (1) CY1120358T1 (es)
DK (1) DK2125850T3 (es)
ES (2) ES2676308T3 (es)
HR (1) HRP20180912T1 (es)
HU (2) HUE052444T2 (es)
IL (2) IL199984A0 (es)
LT (1) LT2125850T (es)
MX (2) MX348083B (es)
NZ (2) NZ601347A (es)
PL (2) PL2125850T3 (es)
PT (2) PT3412678T (es)
RU (1) RU2478643C2 (es)
SI (1) SI2125850T1 (es)
TR (1) TR201810589T4 (es)
TW (2) TWI453015B (es)
WO (1) WO2008091554A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5113978B2 (ja) * 2003-11-21 2013-01-09 味の素株式会社 グルタミン酸誘導体の有機アミン塩及びその利用
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
PL2305245T3 (pl) * 2004-05-14 2019-05-31 Merck Sharp & Dohme Leczenie chorób związanych ze stosowaniem antybiotyków (poantybiotykowych)
US7935377B2 (en) * 2004-06-04 2011-05-03 Ajinomoto Co., Inc. Crystals of free (2R, 4R)-monatin and use thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
EP2170062A4 (en) * 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
UA115523C2 (uk) * 2010-02-05 2017-11-27 Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка" Тверді форми макроциклічних інгібіторів кінази
MX2012013372A (es) * 2010-05-18 2013-05-01 Optimer Pharmaceuticals Inc Metodos para tratar infecciones bacterianas recurrentes.
WO2012106722A2 (en) * 2011-02-04 2012-08-09 Optimer Pharmaceuticals, Inc. Treatment of bacterial infections
WO2013138748A1 (en) * 2012-03-16 2013-09-19 Optimer Pharmaceuticals, Inc. Prevention of clostridium difficile infection in high risk patients
US8722863B2 (en) * 2012-05-10 2014-05-13 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
WO2013170142A1 (en) 2012-05-10 2013-11-14 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
JO3464B1 (ar) * 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
EP2964196A1 (en) 2013-03-08 2016-01-13 Cipla Limited Pharmaceutical compositions for rectal administration
CN103275152B (zh) * 2013-05-29 2015-11-18 华北制药集团新药研究开发有限责任公司 一种高纯度非达霉素的制备方法
CN103275153B (zh) * 2013-06-27 2016-03-23 华北制药集团新药研究开发有限责任公司 一种非达霉素晶体的制备方法
CN104560766B (zh) * 2013-10-16 2017-07-28 浙江海正药业股份有限公司 一种游动放线菌菌株及其应用
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
WO2015127955A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. A new polymorph of tiacumicin b and process for preparation thereof
EP3110826A1 (en) 2014-02-25 2017-01-04 OLON S.p.A. Process for preparing novel forms of tiacumicin b
JP2017507994A (ja) * 2014-03-18 2017-03-23 クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ チアクマイシンｂの新たな多形及び新たな固体状態
CA2948400A1 (en) 2014-05-09 2015-11-12 Astellas Pharma Europe Ltd Treatment regimen tiacumicin compound
WO2015175695A1 (en) * 2014-05-13 2015-11-19 Debrabander Jef Small molecule compounds selective against gram-negative bacterial infections
CN104098637B (zh) 2014-07-09 2017-01-04 浙江海正药业股份有限公司 一种纯化非达霉素的方法
MA42309A (fr) 2015-07-03 2021-03-24 Astellas Pharma Europe Ltd Nouveau composé de tiacumicine pour régime posologique
CN112190589A (zh) * 2020-11-17 2021-01-08 首都医科大学附属北京胸科医院 非达霉素在制备抑制鸟分枝杆菌活性的产品中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1458512A (en) * 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4321361A (en) * 1980-06-12 1982-03-23 Eli Lilly And Company Demycinosyltylosin and process for its production
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5583115A (en) 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US5767096A (en) 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
JP2000072760A (ja) 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
CA2404938C (en) 2000-04-28 2011-11-01 Kosan Biosciences, Inc. Production of polyketides
AU2001211213A1 (en) 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
US20070105791A1 (en) * 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
CA2494742C (en) * 2002-07-29 2015-05-12 Optimer Pharmaceuticals, Inc. Tiacumicin production
PL2305245T3 (pl) 2004-05-14 2019-05-31 Merck Sharp & Dohme Leczenie chorób związanych ze stosowaniem antybiotyków (poantybiotykowych)
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
EP1848273A4 (en) * 2005-01-31 2010-02-24 Optimer Pharmaceuticals Inc 18-PIECE MACROCYCLES AND ITS ANALOG
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
CA2626698C (en) 2005-10-21 2015-12-01 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US20080176927A1 (en) 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
ZA200905337B (en) * 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Also Published As

Publication number Publication date
ES2821384T3 (es) 2021-04-26
DK2125850T3 (en) 2018-07-30
TW200840562A (en) 2008-10-16
JP5764168B2 (ja) 2015-08-12
CA2676061A1 (en) 2008-07-31
BRPI0806878A2 (pt) 2014-06-24
MX2009007730A (es) 2009-08-07
CA2676061C (en) 2016-01-19
RU2478643C2 (ru) 2013-04-10
CA2880860A1 (en) 2008-07-31
SI2125850T1 (en) 2018-08-31
HRP20180912T1 (hr) 2018-07-27
KR20090117924A (ko) 2009-11-16
PT3412678T (pt) 2020-09-29
US7863249B2 (en) 2011-01-04
EP2125850B1 (en) 2018-05-30
TWI453015B (zh) 2014-09-21
EP2468761A1 (en) 2012-06-27
AU2008209580A1 (en) 2008-07-31
US20090163428A1 (en) 2009-06-25
US8883986B2 (en) 2014-11-11
US7378508B2 (en) 2008-05-27
RU2009131727A (ru) 2011-02-27
JP5468388B2 (ja) 2014-04-09
CN102746353A (zh) 2012-10-24
TR201810589T4 (tr) 2018-08-27
NZ601347A (en) 2013-11-29
CN101663312B (zh) 2013-10-23
PL3412678T3 (pl) 2020-12-14
JP2010516681A (ja) 2010-05-20
EP3412678B1 (en) 2020-08-19
EP2125850A1 (en) 2009-12-02
PL2125850T3 (pl) 2018-08-31
WO2008091554A1 (en) 2008-07-31
TWI425942B (zh) 2014-02-11
PT2125850T (pt) 2018-07-11
US20100081800A1 (en) 2010-04-01
EP3412678A1 (en) 2018-12-12
LT2125850T (lt) 2018-08-10
NZ578697A (en) 2012-08-31
JP2013241440A (ja) 2013-12-05
IL199984A0 (en) 2010-04-15
US8859510B2 (en) 2014-10-14
US20080194497A1 (en) 2008-08-14
HUE052444T2 (hu) 2021-05-28
US20130252914A1 (en) 2013-09-26
KR20150006082A (ko) 2015-01-15
ES2676308T3 (es) 2018-07-18
TW201350114A (zh) 2013-12-16
HUE039395T2 (hu) 2018-12-28
CY1120358T1 (el) 2019-07-10
IL220255A0 (en) 2012-07-31
US20070259949A1 (en) 2007-11-08
CN101663312A (zh) 2010-03-03

Similar Documents

Publication Publication Date Title
MX348083B (es) Polimorfos macrociclicos, composiciones que comprenden tales polimorfos, y metodos para su uso y fabricacion.
WO2005112990A3 (en) Treatment of diseases associated with the use of antibiotics
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
TW200734344A (en) Antibacterial agents
MY150958A (en) Compounds for the treatment of multi-drug resistant bacterial infections
MX347688B (es) Moleculas pequeñas que contienen boro.
HK1096396A1 (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
WO2010063996A3 (en) Antibacterial compounds
MX2014001599A (es) 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con piperidinilo antibacterianas.
JO3611B1 (ar) سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
WO2006120563A3 (en) Antibacterial agents
MX2011008043A (es) Derivados de actagardina.
MY148124A (en) Preparation of a crystalline antibiotic substance
MX2014001598A (es) 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con homopiperidinilo antibacterianas.
WO2007096703A3 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
WO2010019511A3 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
WO2011019839A3 (en) Glycopeptide and lipoglycopeptide antibiotics with improved solubility
MX2010004407A (es) Antibioticos de carbacefem beta-lactama.
NZ545472A (en) 7-(4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl)quinolonecarboxylic acid derivative
WO2006094082A3 (en) Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity
WO2014165126A3 (en) Derivatized 3-styryl-cephalosporins
TW200640942A (en) New macrolides
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
MX2018002033A (es) Agentes antibacterianos que comprenden una pirazino[2,3-b] [1,4]oxazin-3-ona o un sistema de anillo relacionado.
WO2006018807A8 (en) Crystalline forms of cefdinir